Cathie Wood's Ark Invest Bets On Biotech With CRISPR Therapeutics Investment, Exits Roblox

Cathie Wood, the founder of Ark Invest, has made a significant move in the biotech sector by investing in CRISPR Therapeutics (CRSP), a gene editing company focused on developing gene-based medicines for serious human diseases using its CRISPR/Cas9 platform. This investment aligns with Ark Invest's strategy of focusing on innovative technologies and disruptive growth opportunities. Meanwhile, Ark Invest has exited its position in Roblox Corp. (RBLX), a popular gaming platform, indicating a shift in their investment priorities.

CRISPR Therapeutics' innovative CRISPR/Cas9 gene editing technology has the potential to revolutionize medicine by enabling precise, targeted changes to DNA. The company has a strong pipeline of therapeutic programs across various disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. Its lead product candidate, Casgevy, is the first CRISPR-based gene therapy approved for treating sickle cell disease and beta thalassemia, demonstrating the company's leadership in the field.

Ark Invest's purchase of CRSP shares for both its ARK Genomic Revolution ETF (ARKG) and Ark Innovation ETF (ARKK) indicates their confidence in the company's potential for growth and success. This investment is a strategic move for Ark Invest, as it positions them at the forefront of the gene editing revolution and aligns with their long-term growth-oriented strategy.

In contrast, Ark Invest's exit from Roblox Corp. suggests a reassessment of the company's long-term potential. Factors such as market saturation, competition, financial performance, and technological advancements may have contributed to Ark Invest's decision to sell their holdings in RBLX. This move highlights Ark Invest's commitment to evaluating the long-term prospects of their investments and adjusting their portfolio accordingly.

CRISPR Therapeutics' innovative technology, strong pipeline, and regulatory approvals make it an attractive investment opportunity in the biotech sector. Ark Invest's decision to bet on CRSP reflects their confidence in the company's potential for growth and success. As the biotech sector continues to evolve, investors like Ark Invest will play a crucial role in supporting innovative companies and driving progress in the field.



As CRISPR Therapeutics continues to develop its pipeline and commercialize its therapies, investors can expect to see significant growth in the company's revenue and earnings. The following table provides a forecast of CRISPR Therapeutics' revenue and EPS for the next five years:

| Year | Revenue (in $ million) | EPS (in $ million) |
| --- | --- | --- |
| 2024 | 15.91 | -5.26 |
| 2025 | 130.67 | -5.12 |
| 2026 | 603.14 | -3.18 |
| 2027 | Pro | Pro |
| 2028 | Pro | Pro |
| 2029 | Pro | Pro |

These forecasts indicate a significant increase in CRISPR Therapeutics' revenue and EPS over the next five years, reflecting the company's growth potential and the market's appetite for innovative biotech therapies.

In conclusion, Cathie Wood's Ark Invest has made a strategic move in the biotech sector by investing in CRISPR Therapeutics, a company at the forefront of gene editing technology. This investment aligns with Ark Invest's long-term growth-oriented strategy and positions them well in the rapidly evolving biotech sector. Meanwhile, Ark Invest's exit from Roblox Corp. demonstrates their commitment to evaluating the long-term prospects of their investments and adjusting their portfolio accordingly. As the biotech sector continues to grow and innovate, investors like Ark Invest will play a crucial role in supporting promising companies and driving progress in the field.